Price movement over the last 24 hours
Alcon AG vs Gartner Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Gartner Inc trades at $133.8 (market cap $9.43B). The key difference: Alcon AG is far larger — about 3.5× Gartner Inc's market cap, and Alcon AG pays a 0.54% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| ALC | IT | |
|---|---|---|
Market Cap | $32.69B | $9.43B |
Sector | Health | Technology |
52-Week High | $92.22 | $399.15 |
52-Week Low | $62.02 | $125.68 |
Enterprise Value | $36.28B | $11.02B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Gartner (IT) trades at $140.80, up 3.29% today, with a bearish technical signal but strong fundamental profitability. Recent earnings consistently beat estimates, with Q1 2026 EPS of $3.32 exceeding the $2.99 forecast. The company maintains robust margins, including a 68.99% gross profit margin and 11.44% net income margin, though 2025 net cash flow was negative $210.63 million. Analyst consensus price target is $158.00, suggesting potential upside from current levels.
The stock offers value with a P/E of 13.35 and P/S of 1.54, but high P/B of 142.72 and negative cash flow trends pose risks. Competitive pressures in IT consulting and reliance on enterprise spending are headwinds. Institutional sentiment is mixed with 27.78% buy ratings, indicating cautious optimism amid operational challenges.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →